Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05672030 · ClinicalTrials.gov registry record
Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 30
- Enrollment target
NCT05672030: Completed study, sponsored by Brigham and Women's Hospital.
NCT05672030 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05672030 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The overarching hypothesis of this proposal is that IL-5 acts on multiple sinus tissue cell types, including plasma cells and epithelial cells, to promote immune dysregulation, and that inhibition of IL-5 affects several relevant effector pathways that lead to clinical benefit.
Primary Outcome
We will determine the number of participants from whom a transcriptional profile of nasal polyp plasma cells is analyzable from bulk RNA sequencing of sorted nasal polyp plasma cells.
Interventions
- OTHER Non-Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-10-01 |
| Est. Completion | 2023-12-01 |
What the finished NCT05672030 record still lists
NCT05672030 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional is the first listed.
NCT05672030 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05672030 about?
NCT05672030 is a clinical study titled "Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP". The overarching hypothesis of this proposal is that IL-5 acts on multiple sinus tissue cell types, including plasma cells and epithelial cells, to promote immune dysregulation, and that inhibition of IL-5 affects several relevant effector pathways that lead to clinical benefit.
What is the current status of trial NCT05672030?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2022-10-01. Estimated completion is 2023-12-01.
What interventions are being tested in trial NCT05672030?
The interventions under investigation include: Non-Interventional (OTHER).
Who is sponsoring clinical trial NCT05672030?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI